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Abstract
Background: Enterobacteriaceae are currently causing the majority of healthcare-associated infections (HAI) and 
simultaneously expressing increasing levels of antibiotic resistance. The purpose of this study is to assess the in vitro 
sensitivity of MDR strains from the family Enterobacteriaceae to tigecycline in relation to their origin from patients 
hospitalized in intensive care units (ICUs) and non-ICUs. 
Methods: The study involved 156 clinically significant strains of the Enterobacteriaceae family isolated from patients 
with complicated intraabdominal infections (cIAIs) and/or complicated skin and skin structure infections (cSSSIs) 
hospitalized in ICUs and other surgical departments. Tigecycline MICs were determined by Etest. 
Results: The highest percentage of tigecycline non-susceptible (intermediate + resistant strains) in vitro strains 
among the Enterobacteriaceae species were observed for Serratia spp. 77.3%, followed by Citrobacter spp. (76.9%) 
and Enterobacter spp. (70%); whereas K. pneumoniae and E. coli showed 73–73.8% tigecycline susceptibility rates. 
Conclusion: Tigecycline demonstrates a high level of antimicrobial in vitro activity when tested against E. coli and  
K. pneumoniae, even those with the ESBL-phenotype. Tigecycline retained activity against merely 22–30% of Entero-
bacter, Citrobacter and Serratia genera.
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The acronym ESKAPE was proposed to highlight the fact 
that some bacterial species (Enterococcus faecium, Staphy-
lococcus aureus, Klebsiella pneumoniae, Acinetobacter bau-
mannii, Pseudomonas aeruginosa and Enterobacter species) 
effectively “escape” the effects of antibacterial drugs [1]. 
All ESKAPE pathogens are currently causing the majority 
of healthcare-associated infections (HAI) while simultane-
ously expressing increasing levels of antibiotic resistance [2]. 
Therefore, nowadays we are witnessing a  remarkable 
change, which consists of replacing susceptible microbiota 
with hospital strains in the majority of those considered 
multidrug resistant (MDR) [1, 3]. This seems to be not only 
a serious epidemiological and therapeutic dilemma nowa-
days but also poses a real threat of having no antimicrobial 
treatment for “ESKAPE” extensively resistant pathogens 
(XDR) in the nearest future [1, 4, 5].
Tigecycline is an antimicrobial drug belonging to glycyl-
cyclines, registered by the European Medicines Agency (EMA) 
for the treatment of adults with complicated intra-abdominal 
infections (cIAIs) and complicated skin and skin structure infec-
tions (cSSSIs), except for diabetic foot infections [6]. According 
to the European Conference on Infections in Leukemia (ECIL), 
tigecycline could be used as a salvage therapy in leukemic and 
hematopoietic stem cell transplant recipients [7].
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The purpose of this study is to assess the in vitro sen-
sitivity of MDR strains of the Enterobacteriaceae family to 
tigecycline in relation to their origin from patients hospital-
ized in intensive care units (ICUs) and non-ICUs. Our study 
may contribute to the evaluation of the changing trends in 
Enterobacteriaceae drug resistance to antibiotics relevant in 
the treatment of cIAIs and cSSSIs. 
METHODS
The study was approved by the Jagiellonian Univer-
sity Medical College Bioethical Committee (No. KBET/19/ 
/B /2013).
Bacterial isolates
The study involved 156 clinically significant non-dupli-
cate strains of the Enterobacteriaceae family isolated from 
patients with cIAIs and/or cSSSIs hospitalized in intensive 
care units (ICUs) and other surgical (non-ICU) departments 
in specialist hospitals in the area of Cracow during the 
period 2009–2013. The clinical materials were as follows: 
surgical wound exudates — 119 samples; peritoneal fluid 
— 25 samples; blood — 6 samples; and surgical biopsy — 
6 samples.
SPecieS idenTificaTion
Species identification was carried out with API 20 E 
strips (bioMérieux) according to manufacturer’s guidelines.
SuScePTiBiliTy To Tigecycline TeSTing 
Susceptibility to tigecycline was determined by Etest 
(bioMérieux) according to the manufacturer’s procedure on 
freshly prepared Mueller Hinton II Agar (Becton Dickinson). 
Plates were inoculated with 0.5 McF bacterial suspension. 
Culture plates were incubated in ambient air at 35 ± 10C for 
18–20 h. Escherichia coli ATCC 25922 and Klebsiella pneu-
moniae ATCC 700603 strains were used as quality control. 
Results were expressed as an MIC range, as well as MIC50 
and MIC90 values in mg L
-1 units. 
evaluaTion of reSiSTance PaTTernS
The presence of ESBL and AmpC phenotypes in the 
examined isolates was confirmed by a double-disk suscep-
tibility test (DDST) with ceftazidime (Oxoid) and cefotaxime 
(Oxoid) as indicators and amoxicillin (Oxoid), and clavulanic 
acid (Oxoid) as inhibitors of ESBL. The MBL mechanism of 
resistance was detected by DDST with an EDTA disk, a disk 
containing a  metallo-β-lactamase inhibitor and disks of 
ceftazidime (Oxoid) and imipenem (Oxoid) in accordance 
with the recommendations of the Polish National Refer-
ence Centre for Antimicrobial Susceptibility Testing (KORLD), 
based on EUCAST guidelines [8].
STaTiSTical analySiS
A statistical analysis was performed using R Language 
and Environment for Statistical Computing software [9]. 
Comparisons were made using Pearson’s Chi-squared test 
with Yates’ continuity correction, a post hoc test after Kruskal-
-Wallis, with Pairwise comparisons conducted using Wil-
coxon’s rank sum test. The significance level for all statistical 
tests was set at P ≤ 0.05.
RESULTS
Out of the 156 strains tested, 139 (89.10%) had resistance 
phenotypes while 21 (13.46%) were considered generally 
susceptible to the antibiotic being tested. The main resist-
ance phenotype was ESBL produced by 99 (63.46%) strains, 
among which 44 (44.4%) were Klebsiella spp. strains, 18 
(18.2%) — Serratia spp., 17 (17.7%) — E. coli, 11 (11.1%) — 
Enterobacter spp., 6 (6.1%) — Citrobacter spp. ESBL-positive 
strains with nearly the same frequency came from 49 (49.5%) 
ICU and 50 (50.5%) non-ICU patients.
We found that 81 (50.6%) strains were inhibited by tige-
cycline at ≤ 1 mg L-1 (more detailed data are shown in Table 
1 and Fig. 1). 
Among the Enterobacteriaceae species and subsets 
tested, MIC50 values varied from 1 mg L
-1 for all Klebsiella 
spp., E. coli without any resistant phenotype and E. coli ESBL-
phenotype, Enterobacter spp. with AmpC phenotype and 
Serratia spp. without any resistant phenotype to 2 mg L-1 
for Enterobacter spp. ESBL+MBL phenotype. However, MIC90 
values were 3 mg L-1 for all tested species. 
The highest percentage of tigecycline non-susceptible 
(intermediate + resistant strains) in vitro strains among the 
Enterobacteriaceae species was observed for Serratia spp. 
(77.3%), followed by Citrobacter spp. (76.9%) and Entero-
bacter spp. (70%); whereas K. pneumoniae and E. coli showed 
73–73.8% tigecycline susceptibility rates at EUCAST break-
points (Table 1, Fig. 1). 
Moreover, the highest percentage of tigecycline 
non-susceptible in vitro strains among those considered 
resistance-phenotype strains was observed at 93.7% (62, 
14, 11.4, and 6.3% for ESBL phenotype, ESBL+MBL phe-
notype, AmpC phenotype and ESBL+AmpC phenotype, 
respectively), whereas only non-resistant phenotype strains 
showed 6.3% tigecycline susceptibility rates. A comparison 
of the incidence of strains with the ESBL+ phenotype among 
strains sensitive and resistant to tigecycline demonstrated 
a statistically significant difference Citrobacter > Enterobacter 
> Serratia > *Klebsiella > *E. coli (P = 0.02498).
On the basis of the MIC values obtained for individual 
Enterobacteriaceae species, we have found that MIC me-
dian values vary between different species (P = 1.702e-08) 
(Table 2).
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DISCUSSION
It has been proposed to change the acronym ESKAPE 
to ESCAPE (Enterococcus faecium, Staphylococcus aureus, 
Clostridium difficile, Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacteriaceae) to highlight the fact 
that, among others, pathogens belonging to the Enterobac-
teriaceae family can express increasing levels of antibiotic 
resistance. This is becoming an important clinical problem 
Table 1. Comparison of in vitro activity of tigecycline against species belonging to the Enterobacteriaceae family
Organism n
MIC (mg L-1)
S %
MIC range MIC50 MIC90
all K. pneumoniae 44 0.38–2.0 1.0 3.0 73.8
ESBL phenotype 44 0.38–2.0 1.0 3.0 73.8
all E. coli 37 0.032–3.0 1.0 3.0 73
without lactamases 16 0.125–3.0 1.0 3.0 75
ESBL phenotype 17 0.032–3.0 1.0 3.0 64.7
AmpC phenotype 4 0.19–3.0 1.5 3.0 75
all Enterobacter spp. 40 0.38–3.0 1.5 3.0 30
ESBL phenotype 11 0.38–3.0 1.5 3.0 9.1
ESBL + AmpC phenotype 8 0.38–3.0 1.5 3.0 37.5
ESBL + MBL phenotype 10 2.0–3.0 2.0 3.0 0
AmpC phenotype 11 0.38–3.0 1.0 3.0 72.73
all Serratia spp. 22 0.125–3.0 1.5 3.0 22.7
without lactamases 3 0.75–1.5 1.0 3.0 66.67
ESBL phenotype 18 0.75–3.0 1.5 3.0 16.67
AmpC phenotype 1 3.0 – – 0
all Citrobacter spp. 13 0.5–4.0 1.5 3.0 23.1
without lactamases 1 0.75 – – 100
ESBL phenotype 6 0.5–3.0 1.5 3.0 16.67
ESBL + MBL phenotype 1 3.0 – – 0
  AmpC phenotype 5 1.0–4.0 1.5 3.0 20
MIC — minimum inhibitory concentration; MIC50/90 — MICs at which 50% and 90% of the isolates were inhibited, respectively; MIC values are given in mg L-1; %S/ %R — 
susceptible and resistant strains respectively, according to EUCAST breakpoints
Figure 1. Comparison of MIC distribution of tigecycline against the most numerous species of the Enterobacteriaceae family from ICU and non-ICU 
patients
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associated with, on the one hand, reduced therapeutic pos-
sibilities, and on the other, an increase in morbidity, mortal-
ity, healthcare costs including long-term hospitalizations, 
particularly in ICUs [4, 10, 11]. In our discussion, due to the 
broad scope of the topic, we refer to data concerning the 
epidemiological situation in Poland.
The ICU is an environment in which there are interactions 
between the patient vs. the unit vs. bacterial pathogens. 
Patients admitted for treatment in the ICU are in a serious 
condition, immunosuppressed, usually with several under-
lying conditions, previously treated in other departments, 
and they undergo emergency intra-abdominal surgery. The 
patient’s condition influences the length of the ICU stay and 
the type and number of procedures to which the patient 
is subjected (intubation, mechanical ventilation, vascular 
access, parenteral nutrition and other invasive procedures) 
[10, 12, 13]. An important link in the interaction between 
the patient and the ICU environment is the bacterial flora 
present in the unit, which has a high resistance to antibiotics 
(MDR strains) and its ability to quickly colonize the patient, 
environment, and staff [11, 13, 14]. After Rutkowska et al. [11] 
observed that after aproximately a week from the start 
of hospitalization in ICU, 96% of patients demonstrated 
a change in their microbiota, which demonstrated a change 
in their microbiota, which was replaced by pathogens char-
acteristic of a  given hospital department. Gram-negative 
bacilli are predominant in Polish ICUs [11, 15], which was also 
confirmed by our studies [unpublished results]. In our re-
search, the genus Enterobacter was most frequently isolated 
during the ICU stay, followed by K. pneumoniae and E. coli, 
thus supporting other reports [11, 14, 16]. Our results con-
firm that the majority of Enterobacteriaceae strains including 
those from beta-lactamases such as ESBL phenotype situa-
tion in Polish hospitals is in line with the global trend of most 
reported infections being MDR-HAI [10]. In Poland, among 
patients admitted to ICUs, HAI infections make up 25% of 
all infections (45–60%) diagnosed in the course of patients’ 
hospital stay in these units [11]. CSSSIs in Poland are decreas-
ing (6.3% in 2012, 6.9% in 2013, 4.5% in 2014, 1.8% in 2015, 
of all infections) [17]. ICU treatment requires up to three 
times more frequent application of antibiotics than in other 
departments (136 DDD vs. 43 DDD per 100 person days) [14]. 
Often, antibiotic therapy necessitates a wide range of an-
tibiotics, which is aimed at covering the spectrum of MDR 
pathogens. Due to the limited options for treating infections 
with MDR strains, the possibility of applying tigecycline is 
crucial. Tigecycline seems to be used in infections caused 
by many MDR strains, for example ESBL-positive phenotype 
strains [3, 6, 14]. In our study, tigecycline demonstrated the 
highest in vitro sensitivity to K. pneumoniae, even to ESBL+ 
and E. coli strains, a  phenomenon which is confirmed by 
other authors [16, 18–20]. For E. cloacae, other authors have 
shown the high in vitro activity of tigecycline [19], which was 
an opposite result to the one in our study.
In TEST (Tigecycline Evaluation and Surveillance Tri-
al) study for Europe, which was carried out in the period 
2004–2014, 10 medical centres out of 226 were from Poland. 
For K. pneumoniae, E. coli, Enterobacter spp. and S. marcescens, 
the MIC90 values obtained were lower than in our investiga-
tion [21]. When interpreting the above results, it should be 
noted that the level of ESBL+ strains and sensitivity to tige-
cycline varied significantly between countries and microbes. 
TEST results demonstrated differences as regards bacterial 
drug resistance dividing Europe into areas of high and low 
drug susceptibility. Poland was listed among the countries 
with increased resistance to several classes of antibiotics 
(amoxicillin, cefepime, ceftriaxone), including thearpeutic 
treatments used to treat infections caused by ESBL+ strains 
(piperacillin-tazobactam, amikacin, levofloxacin) [21]. 
The similar MIC values obtained in our study for ICU 
and non-ICU strains may be caused by the fact that patients 
are admitted to the ICU from other hospital departments, 
among others, following exacerbation of the disease or 
post-operative complications. This means that they were in 
a hospital environment beforehand for varying durations, 
and were treated numerous times using various antimicro-
bial drugs, which favoured the selection of MDR strains. 
Seeing that patterns of resistance change over time and 
between countries, we are convinced that local data, such as 
our hospital-based study, are necessary to guide clinicians 
in selecting appropriate antimicrobial therapy and in the 
choice of antibiotics for hospital formularies.
CONCLUSIONS
1. Tigecycline demonstrates a high level of antimicrobial 
in vitro activity when tested against E. coli and K. pneu-
Table 2. Post hoc test after Kruskal-Wallis with Pairwise comparisons using Wilcoxon rank sum test
Citrobacter spp. Enterobacter spp. E. coli K. pneumoniae
Enterobacter spp. 0.4472 – – –
E. coli 0.0011* 1.1e-05* – –
K. pneumoniae 0.0021* 0.0026* 0.0126* –
Serratia spp. 0.3471 0.4472 0.0060* 0.0011*
* statistically significant values
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moniae, even those with the ESBL phenotype. However, 
we found that MIC90 was evaluated higher than in other 
trials coming from Poland.
2. Tigecycline retained activity against merely 22–30% of 
Enterobacter, Citrobacter and Serratia which accounted 
for a  large group of pathogens associated with cSSSI 
and cIAI occurring in ICU and non-ICU patients in the 
Małopolska region. 
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